<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 19 May 2021 19:24:11 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>惊呆了，药企55亿净利润“狂砸”67亿现金分红！丽珠、恒瑞、片仔癀……超50家豪气派钱</title><link>https://mp.weixin.qq.com/s/1G0m-A8y6-sCcBytQsA5xg</link><description></description><content:encoded><![CDATA[惊呆了，药企55亿净利润“狂砸”67亿现金分红！丽珠、恒瑞、片仔癀……超50家豪气派钱]]></content:encoded><pubDate>Wed, 19 May 2021 17:35:13 +0800</pubDate></item><item><title>【业绩】合揽超500亿营收！大参林、老百姓5大上市连锁战略曝光</title><link>https://mp.weixin.qq.com/s/mYHnm9zwfoVmu5WYqzk4QA</link><description></description><content:encoded><![CDATA[【业绩】合揽超500亿营收！大参林、老百姓5大上市连锁战略曝光]]></content:encoded><pubDate>Wed, 19 May 2021 17:35:13 +0800</pubDate></item><item><title>【获批】暴涨超300%注射剂！恒瑞拿下首家过评</title><link>https://mp.weixin.qq.com/s/OrLWx8lbpBVyqgltkTyZRg</link><description></description><content:encoded><![CDATA[【获批】暴涨超300%注射剂！恒瑞拿下首家过评]]></content:encoded><pubDate>Wed, 19 May 2021 17:35:13 +0800</pubDate></item><item><title>【热点】第五批国采！50亿大品种，基药与集采规格不一致引关注？</title><link>https://mp.weixin.qq.com/s/mz7MSSfExr6njws-_tq_Lg</link><description></description><content:encoded><![CDATA[【热点】第五批国采！50亿大品种，基药与集采规格不一致引关注？]]></content:encoded><pubDate>Wed, 19 May 2021 17:35:13 +0800</pubDate></item><item><title>2021米思会第一轮议程发布</title><link>https://mp.weixin.qq.com/s/G-P0fkTQIULECra0ViWvww</link><description></description><content:encoded><![CDATA[2021米思会第一轮议程发布]]></content:encoded><pubDate>Tue, 18 May 2021 16:23:22 +0800</pubDate></item><item><title>【重磅】2020中国医药工业百强榜评选启动，研发创新+专业推广“双轮驱动”</title><link>https://mp.weixin.qq.com/s/cDfOEOfKvfl2IHV_fFGVfQ</link><description></description><content:encoded><![CDATA[【重磅】2020中国医药工业百强榜评选启动，研发创新+专业推广“双轮驱动”]]></content:encoded><pubDate>Tue, 18 May 2021 16:23:22 +0800</pubDate></item><item><title>【瞩目】苑东发威！抢$10亿大品种首仿</title><link>https://mp.weixin.qq.com/s/pr-L7Ne2NvQRhEdDL4wOMQ</link><description></description><content:encoded><![CDATA[【瞩目】苑东发威！抢$10亿大品种首仿]]></content:encoded><pubDate>Tue, 18 May 2021 16:23:22 +0800</pubDate></item><item><title>【市场】50亿明星降压药，湖南药企发力</title><link>https://mp.weixin.qq.com/s/Q66u2Nja10zhqsL7tz05jA</link><description></description><content:encoded><![CDATA[【市场】50亿明星降压药，湖南药企发力]]></content:encoded><pubDate>Tue, 18 May 2021 16:23:22 +0800</pubDate></item><item><title>昔日龙头已落幕！注射剂国采后格局大变样，四川汇宇、扬子江、石药大获全胜</title><link>https://mp.weixin.qq.com/s/G4GHIgfnQq6VY3wB3EuuVA</link><description></description><content:encoded><![CDATA[昔日龙头已落幕！注射剂国采后格局大变样，四川汇宇、扬子江、石药大获全胜]]></content:encoded><pubDate>Mon, 17 May 2021 16:51:52 +0800</pubDate></item><item><title>【重磅】成都倍特再有1类新药来袭！早前获批新药已进入临床</title><link>https://mp.weixin.qq.com/s/dOqZH5zCQ9bNq2DvzGWSfA</link><description></description><content:encoded><![CDATA[【重磅】成都倍特再有1类新药来袭！早前获批新药已进入临床]]></content:encoded><pubDate>Mon, 17 May 2021 16:51:52 +0800</pubDate></item><item><title>【火爆】扬子江将收获4个高端仿制药，冲击口服降糖药国产第二家</title><link>https://mp.weixin.qq.com/s/m8BnUzcngK919orPhjPSyA</link><description></description><content:encoded><![CDATA[【火爆】扬子江将收获4个高端仿制药，冲击口服降糖药国产第二家]]></content:encoded><pubDate>Mon, 17 May 2021 16:51:52 +0800</pubDate></item><item><title>【焦点】主流抗ED药大卖35亿，海思科首仿产品劲敌来了</title><link>https://mp.weixin.qq.com/s/GZUNufrZ7tGih3pVYvH9mw</link><description></description><content:encoded><![CDATA[【焦点】主流抗ED药大卖35亿，海思科首仿产品劲敌来了]]></content:encoded><pubDate>Mon, 17 May 2021 16:51:52 +0800</pubDate></item><item><title>天境生物：相信“可能性”，用创新破解临床难题</title><link>https://mp.weixin.qq.com/s/rGvA0OwtHnlYTqX75JAEGQ</link><description></description><content:encoded><![CDATA[天境生物：相信“可能性”，用创新破解临床难题]]></content:encoded><pubDate>Sun, 16 May 2021 07:55:36 +0800</pubDate></item><item><title>白马股6连涨市值大增400亿，老牌药企接连被罚，国药、恒瑞......20家医药企业厉害了</title><link>https://mp.weixin.qq.com/s/H-fVissiLCDqtmwPc9urpg</link><description></description><content:encoded><![CDATA[白马股6连涨市值大增400亿，老牌药企接连被罚，国药、恒瑞......20家医药企业厉害了]]></content:encoded><pubDate>Sat, 15 May 2021 07:56:36 +0800</pubDate></item><item><title>【深度】前沿生物：向艾滋病治疗新天地挺进</title><link>https://mp.weixin.qq.com/s/ysuWfCtgmrtySWUPdQTa5A</link><description></description><content:encoded><![CDATA[【深度】前沿生物：向艾滋病治疗新天地挺进]]></content:encoded><pubDate>Sat, 15 May 2021 07:56:36 +0800</pubDate></item><item><title>抢跑眼科黄金赛道！药企3800万拿下13款滴眼剂，扬子江、齐鲁、兴齐……9款滴眼液亮了</title><link>https://mp.weixin.qq.com/s/jMt8GUJwOfzNB1PUVceyAw</link><description></description><content:encoded><![CDATA[抢跑眼科黄金赛道！药企3800万拿下13款滴眼剂，扬子江、齐鲁、兴齐……9款滴眼液亮了]]></content:encoded><pubDate>Fri, 14 May 2021 16:09:02 +0800</pubDate></item><item><title>【瞩目】厉害了！石药集团两大重磅品种过评</title><link>https://mp.weixin.qq.com/s/zerLkWNBiYvlBJrhV5fBUQ</link><description></description><content:encoded><![CDATA[【瞩目】厉害了！石药集团两大重磅品种过评]]></content:encoded><pubDate>Fri, 14 May 2021 16:09:02 +0800</pubDate></item><item><title>【市场】恒瑞慌了？40亿造影剂第6家过评企业来了</title><link>https://mp.weixin.qq.com/s/uQH-rksWyAOqmbPmObuE4A</link><description></description><content:encoded><![CDATA[【市场】恒瑞慌了？40亿造影剂第6家过评企业来了]]></content:encoded><pubDate>Fri, 14 May 2021 16:09:02 +0800</pubDate></item><item><title>【重磅】山东药企将拿下$7亿大品种首仿</title><link>https://mp.weixin.qq.com/s/g_gFCOINtZaAqN4gK4QWbQ</link><description></description><content:encoded><![CDATA[【重磅】山东药企将拿下$7亿大品种首仿]]></content:encoded><pubDate>Fri, 14 May 2021 16:09:02 +0800</pubDate></item><item><title>奥赛康、甘李、康弘、济川……高毛利药企曝光！这些爆款产品竟有九成毛利</title><link>https://mp.weixin.qq.com/s/zhpMhdAEiUK7jNNLbieg3w</link><description></description><content:encoded><![CDATA[奥赛康、甘李、康弘、济川……高毛利药企曝光！这些爆款产品竟有九成毛利]]></content:encoded><pubDate>Thu, 13 May 2021 17:11:30 +0800</pubDate></item></channel></rss>